Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose.

From 2025, Health Technology Developers (HTDs) have to submit EU HTA dossiers. The joint clinical assessment (JCA) aims to streamline HTA processes and access to medicinal products across Europe. Currently, German HTA bodies IQWiG and G-BA actively shape the JCA methodology.

Approved drugs ezetimibe and disulfiram enhance mitochondrial Ca uptake and suppress cardiac arrhythmogenesis.

Background And Purpose: Treatment of cardiac arrhythmia remains challenging due to severe side effects of common anti-arrhythmic drugs. We previously demonstrated that mitochondrial Ca uptake in cardiomyocytes represents a promising new candidate structure for safer drug therapy. However, druggable agonists of mitochondrial Ca uptake suitable for preclinical and clinical studies are still missing.

Suppression of Arrhythmia by Enhancing Mitochondrial Ca Uptake in Catecholaminergic Ventricular Tachycardia Models.

Cardiovascular disease-related deaths frequently arise from arrhythmias, but treatment options are limited due to perilous side effects of commonly used antiarrhythmic drugs. Cardiac rhythmicity strongly depends on cardiomyocyte Ca handling and prevalent cardiac diseases are causally associated with perturbations in intracellular Ca handling. Therefore, intracellular Ca transporters are lead candidate structures for novel and safer antiarrhythmic therapies.